What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?

Baron Funds' "Baron Health Care Fund" Q3 2024 investor letter reports a 5.81% appreciation, slightly below the benchmark. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was highlighted, with a -17.